Joint Oncologie and Merck Phase II Trial Announced for Gastric and Gastroesophageal Cancers

September 9, 2019

New Report Highlights Risks of U.S. Drug Reimportation

Oncologie and Merck will launch a phase II trial to investigate Merck’s Keytruda (pembrolizumab) and Oncologie’s bavituximab, an antibody that blocks the activity of phosphatidylserine (PS) in advanced gastric or gastroesophageal cancer. International trials like this one — enrolling patients in the United States, the UK, Korea, and Taiwan — are a particular specialty at Yourway.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Global Clinical Supplies Group (GCSG)

October 14-16, 2025
Hungary, Budapest

Schedule a Meeting

Clinical Outsourcing Group (COG)

October 21-22, 2025
Burlingame, California

Schedule a Meeting

Media

Articles

Keeping trials on track: Prioritizing communication in decentralized trials

Open chat

Hello! How can I help you?